Company intelligence / Profile preview

HopeMed

Shanghai, Shanghai, Chinahopemedinc.com ↗
Ownership
Private
Employees
~80
Development stage
Other
01

Overview

HopeMed is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for endocrine, cardiovascular, and women's health diseases. The company's lead asset, HMI-115, is a first-in-class monoclonal antibody targeting the prolactin receptor, which was licensed from Bayer for global development and commercialization. HopeMed is currently advancing HMI-115 through multiple Phase 2 clinical trials for indications such as endometriosis and androgenetic alopecia. Founded by Professor Rui-Ping Xiao of Peking University, the company bridges high-quality academic research with global drug development expertise to address significant unmet medical needs.

Therapeutic areas
NephrologyWomen's HealthCardiovascularEndocrinologyDermatology
Modalities
Monoclonal antibodySmall molecule
Industry
Biotech
02

Drug pipeline

6 assets

HMI-115

3

5 more assets in the full pipeline.

03

Partnerships

Bayer

Beyond the preview

Go deeper on HopeMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HopeMed.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call